arsenic has been researched along with MS (Multiple Sclerosis) in 11 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 5 (45.45) | 18.7374 |
1990's | 1 (9.09) | 18.2507 |
2000's | 1 (9.09) | 29.6817 |
2010's | 4 (36.36) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ammatuna, E; Ardiri, D; Centonze, D; Divona, M; Lo-Coco, F; Montefusco, E; Pacilli, M | 1 |
COMPSTON, ND | 1 |
MILLAR, JH | 1 |
Low-Beer, TS; Robertson, DA | 1 |
Bawden-Smith, J; Donaghy, FA; McAnulty, JM | 1 |
Dick, G; Gay, D | 1 |
Aliomrani, M; Ghahremani, MH; Khoshayand, MR; Sahraian, MA; Sharifzadeh, M; Shirkhanloo, H | 1 |
Lee, CT; Tsai, CP | 1 |
Ahmadi, Y; Faghfoori, Z; Ghorbanihaghjo, A; irannejad, VS; Yousefi, B | 1 |
Alizadeh-Ghodsi, M; Ebrahimi-Kalan, A; Shiri-Shahsavar, MR; Yousefi, B; Zavvari, A | 1 |
Gould, CE; Horksy, SJ; Warren, HV | 1 |
11 other study(ies) available for arsenic and MS (Multiple Sclerosis)
Article | Year |
---|---|
Use of arsenic trioxide in secondary acute promyelocytic leukemia developing after treatment of multiple sclerosis with mitoxantrone.
Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Enzyme Inhibitors; Humans; Leukemia, Promyelocytic, Acute; Male; Mitoxantrone; Multiple Sclerosis; Oxides; Remission Induction; Topoisomerase II Inhibitors; Treatment Outcome | 2009 |
Disseminated sclerosis; assessment of the effect of treatment on the course of the disease.
Topics: Arsenicals; Histamine H1 Antagonists; Humans; Hyperthermia, Induced; Multiple Sclerosis | 1953 |
Evaluation of the treatment of disseminated sclerosis with arsenicals.
Topics: Arsenic; Arsenicals; Humans; Multiple Sclerosis; Sclerosis | 1951 |
Long term consequences of arsenical treatment for multiple sclerosis.
Topics: Adult; Arsenic; Arsenic Trioxide; Arsenicals; Carcinoma, Transitional Cell; Humans; Hypertension, Portal; Male; Multiple Sclerosis; Oxides; Urinary Bladder Neoplasms | 1983 |
Toxic little black pills.
Topics: Adult; Arsenic Poisoning; Arsenicals; Female; Humans; Multiple Sclerosis; Poisoning | 1996 |
Is multiple sclerosis caused by an oral spirochaete?
Topics: Acute Disease; Arsenicals; Central Nervous System; Chronic Disease; Humans; Mouth; Multiple Sclerosis; Sinusitis; Sphenoid Sinus; Spirochaetales Infections | 1986 |
Correlation between heavy metal exposure and GSTM1 polymorphism in Iranian multiple sclerosis patients.
Topics: Adult; Arsenic; Cadmium; Female; Genetic Predisposition to Disease; Genotype; Glutathione S-Transferase pi; Glutathione Transferase; Humans; Iran; Male; Middle Aged; Multiple Sclerosis; Oxidative Stress; Polymorphism, Genetic; Young Adult | 2017 |
Multiple sclerosis incidence associated with the soil lead and arsenic concentrations in Taiwan.
Topics: Arsenic; Environmental Exposure; Female; Humans; Incidence; Lead; Male; Multiple Sclerosis; National Health Programs; Smoking; Soil Pollutants; Sunlight; Taiwan | 2013 |
Serum arsenic and lipid peroxidation levels in patients with multiple sclerosis.
Topics: Adult; Arsenic; Case-Control Studies; Female; Humans; Malondialdehyde; Multiple Sclerosis; Spectrophotometry, Atomic; Thiobarbituric Acid Reactive Substances | 2014 |
The hypothetical roles of arsenic in multiple sclerosis by induction of inflammation and aggregation of tau protein: A commentary.
Topics: Animals; Apoptosis; Arsenic; Brain; Cell Line; Disease Progression; Humans; Inflammation; Lipid Peroxidation; Malondialdehyde; Microtubules; Multiple Sclerosis; Neurons; Phosphorylation; Protein Aggregation, Pathological; tau Proteins | 2018 |
Quantitative analysis of zinc, copper, lead, molybdenum, bismuth, mercury and arsenic in brain and other tissues from multiple sclerosis and non-multiple sclerosis cases.
Topics: Arsenic; Bismuth; Brain Chemistry; Copper; Humans; Lead; Mercury; Metals; Molybdenum; Multiple Sclerosis; Tissue Distribution; Zinc | 1983 |